Imperial College London
Alternate

ProfessorPeterCollins

Faculty of Medicine, National Heart & Lung Institute

Professor of Clinical Cardiology
 
 
 
//

Contact

 

+44 (0)20 7351 8112peter.collins

 
 
//

Location

 

Chelsea WingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Moussa:2022:ehjcvp/pvaa133,
author = {Moussa, O and Ardissino, M and Vincent, M and Hines, O and Amin, R and Eichhorn, C and Tang, AR and Collins, P and Purkayastha, S},
doi = {ehjcvp/pvaa133},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
pages = {179--186},
title = {Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity score matched cohort study},
url = {http://dx.doi.org/10.1093/ehjcvp/pvaa133},
volume = {8},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Aims:The rising prevalence of obesity and its associated comorbidities represent a growing public health issue; in particular, obesity is known to be a major risk factor for cardiovascular disease. Despite the evidence behind the efficacy of orlistat in achieving weight loss in patients with obesity, no study thus far has quantified its long-term effect on cardiovascular outcomes. The purpose of this study is to explore long-term cardiovascular outcomes after orlistat therapy.Methods and results:A propensity-score matched cohort study was conducted on the nation-wide electronic primary and integrated secondary healthcare records of the Clinical Practice Research Datalink (CPRD). The 36 876 patients with obesity in the CPRD database who had completed a course of orlistat during follow-up were matched on a 1:1 basis with equal numbers of controls who had not taken orlistat. Patients were followed up for a median of 6 years for the occurrence of the primary composite endpoint of major adverse cardiovascular events (fatal or non-fatal myocardial infarction or ischaemic stroke), and a number of secondary endpoints including primary endpoint components individually, the occurrence of new-onset heart failure, coronary revascularization, new chronic kidney disease stage III+ (CKD3+), and all-cause mortality. During the median study follow-up of 6 years, the occurrence of major adverse cardiovascular events was lower in the orlistat cohort [hazard ratio (HR) 0.74; 95% confidence interval (CI) 0.66–0.83, P < 0.001]. Patients who took orlistat experienced lower rates of myocardial infarction (HR 0.77; 95% CI 0.66–0.88, P < 0.001) and ischaemic stroke (HR 0.68; 95% CI 0.56 to −0.84, P < 0.001) as well as new-onset heart failure (HR 0.79; 95% CI 0.67–0.94, P = 0.007). There was no differences in revascularization rates (HR 1.12; 95% CI 0.91–1.38, P = 0.27)
AU  - Moussa,O
AU  - Ardissino,M
AU  - Vincent,M
AU  - Hines,O
AU  - Amin,R
AU  - Eichhorn,C
AU  - Tang,AR
AU  - Collins,P
AU  - Purkayastha,S
DO  - ehjcvp/pvaa133
EP  - 186
PY  - 2022///
SN  - 2055-6845
SP  - 179
TI  - Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity score matched cohort study
T2  - European Heart Journal - Cardiovascular Pharmacotherapy
UR  - http://dx.doi.org/10.1093/ehjcvp/pvaa133
UR  - https://academic.oup.com/ehjcvp/article/8/2/179/6274862?login=true
UR  - http://hdl.handle.net/10044/1/85011
VL  - 8
ER  -
Download